Biomerica
Market Cap
US$26.7m
Last Updated
2020/02/22 00:12 UTC
Data Sources
Company Financials +
Executive Summary
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Biomerica's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMRA has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.1%
BMRA
-1.3%
US Medical Equipment
-1.0%
US Market
1 Year Return
8.2%
BMRA
19.7%
US Medical Equipment
18.0%
US Market
Return vs Industry: BMRA underperformed the US Medical Equipment industry which returned 19.7% over the past year.
Return vs Market: BMRA underperformed the US Market which returned 18% over the past year.
Shareholder returns
| BMRA | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.1% | -1.3% | -1.0% |
| 30 Day | -8.5% | -0.9% | 0.6% |
| 90 Day | -7.7% | 7.0% | 7.9% |
| 1 Year | 8.2%8.2% | 20.6%19.7% | 20.4%18.0% |
| 3 Year | 9.5%9.5% | 79.4%74.4% | 48.0%38.5% |
| 5 Year | 236.2%236.2% | 115.3%92.8% | 72.2%53.3% |
Price Volatility Vs. Market
How volatile is Biomerica's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
What Type Of Shareholder Owns Biomerica, Inc.'s (NASDAQ:BMRA)?2 weeks ago | Simply Wall St
When Can We Expect A Profit From Biomerica, Inc. (NASDAQ:BMRA)?1 month ago | Simply Wall St
How Does Investing In Biomerica, Inc. (NASDAQ:BMRA) Impact The Volatility Of Your Portfolio?Valuation
Is Biomerica undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMRA ($2.76) is trading below our estimate of fair value ($43.59)
Significantly Below Fair Value: BMRA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMRA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: BMRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BMRA is overvalued based on its PB Ratio (8.1x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Biomerica forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
42.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: BMRA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BMRA's is expected to become profitable in the next 3 years.
Revenue vs Market: BMRA's revenue (29.6% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: BMRA's revenue (29.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BMRA's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Biomerica performed over the past 5 years?
-36.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMRA is currently unprofitable.
Growing Profit Margin: BMRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of -36.4% per year.
Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.7%).
Return on Equity
High ROE: BMRA has a negative Return on Equity (-72.74%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Biomerica's financial position?
Financial Position Analysis
Short Term Liabilities: BMRA's short term assets ($4.5M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: BMRA's short term assets ($4.5M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: BMRA is debt free.
Reducing Debt: BMRA has not had any debt for past 5 years.
Balance Sheet
Inventory Level: BMRA has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if BMRA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BMRA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BMRA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -27.5% each year
Next Steps
Dividend
What is Biomerica's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BMRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BMRA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BMRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
16.6yrs
Average board tenure
CEO
Zackary Irani (53yo)
22.8yrs
Tenure
US$328,906
Compensation
Mr. Zackary S. Irani has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President and Chairman of ReadySc ...
CEO Compensation Analysis
Compensation vs Market: Zackary's total compensation ($USD328.91K) is below average for companies of similar size in the US market ($USD522.55K).
Compensation vs Earnings: Zackary's compensation has increased whilst the company is unprofitable.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 22.8yrs | US$328.91k | 9.34% $2.5m | |
| CFO, Treasurer | 22.8yrs | US$146.68k | 7.46% $2.0m | |
| Chairman of Strategic Advisory Board | 0yrs | no data | no data | |
| Independent Director | 20.7yrs | US$42.77k | 1.75% $466.1k | |
| Independent Director | 3.6yrs | US$42.77k | 0.19% $50.5k | |
| Independent Director | 20.3yrs | US$61.10k | 1.62% $432.8k | |
| Member of Strategic Advisory Board | 1.8yrs | no data | no data | |
| Independent Director | 12.8yrs | US$52.77k | 0.72% $191.7k | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data |
16.6yrs
Average Tenure
65yo
Average Age
Experienced Board: BMRA's board of directors are seasoned and experienced ( 16.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.
Top Shareholders
Company Information
Biomerica, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biomerica, Inc.
- Ticker: BMRA
- Exchange: NasdaqCM
- Founded: 1971
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$26.703m
- Shares outstanding: 9.89m
- Website: https://www.biomerica.com
Number of Employees
Location
- Biomerica, Inc.
- 17571 Von Karman Avenue
- Irvine
- California
- 92614
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BMRA | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 1975 |
Biography
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point of care and clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient’s diet can alleviate the patient’s IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/22 00:12 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/11/30 |
| Annual Earnings | 2019/05/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.